CCP
NTLA icon

Cardan Capital Partners’s Intellia Therapeutics NTLA Stock Holding History

Cardan Capital Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,100
Closed -$340K – 253
2021
Q2 		$340K Sell
2,100
-1,510
-42% -$118K 0.04% 194
2021
Q1 		$290K Sell
3,610
-800
-18% -$53.7K 0.03% 187
2020
Q4 		$240K Buy
+4,410
New +$160K 0.03% 203

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Cardan Capital Partners's NTLA Position: Q3 2021 in Review

Cardan Capital Partners sold out of Intellia Therapeutics (NTLA) in Q3 2021, closing a stake of 2,100 shares — an estimated $340K sold.

Cardan Capital Partners first reported a position in NTLA in Q4 2020 and held it in 3 quarters. The position peaked at $340K in Q2 2021. 365 funds tracked by Wall St. Rank hold NTLA as of Q3 2021.

  • Cardan Capital Partners reported no remaining Intellia Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Cardan Capital Partners sold 2,100 Intellia Therapeutics shares in Q3 2021, an estimated $340K.
  • Cardan Capital Partners first reported a position in Intellia Therapeutics in Q4 2020 and held it in 3 quarters.
  • Cardan Capital Partners's Intellia Therapeutics position peaked at $340K in Q2 2021.
  • 365 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2021.

Based on Cardan Capital Partners's 13F filing for Q3 2021, filed 25 Oct 2021.